Literature DB >> 10406178

Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?

I Nakano1, Y Fukuda, Y Katano, S Nakano, T Kumada, T Hayakawa.   

Abstract

BACKGROUND/AIMS: The amino acid sequence of NS5A2209-2248, named the "interferon sensitivity-determining region" (ISDR), has been reported to correlate with responsiveness of interferon (IFN) therapy to patients with the hepatitis C virus (HCV) genotype-1b, by several Japanese authors. However, European authors have failed to find this phenomenon, suggesting a difference in HCV-1b isolates between Japan and Europe.
METHODS: We compared the HCV-1b nucleotide sequences of our Japanese patients and those of other countries quoted from GenBank, using the envelope 1 sequence.
RESULTS: A phylogenetic tree analysis revealed two characteristic groups from a geographical viewpoint: one group (NJ group) consists of almost entirely non-Japanese isolates, and the other (J group) of almost entirely Japanese isolates. The isolates other than the NJ and J groups are characterized by their specific nucleotide residue, constructing an individual group (W group). Japanese HCV-1b isolates consist of the J group and W group (approximately 40% and 60%, respectively). Comparative study between the two groups in Japanese patients treated with IFN revealed a strong correlation between ISDR type and IFN responsiveness only in the J group, but not in the W group.
CONCLUSIONS: These observations convinced us that the existence of the Japan-specific J group is one reason why the ISDR system is useful only in Japan.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10406178     DOI: 10.1016/s0168-8278(99)80254-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  10 in total

1.  Management of chronic hepatitis C and prevention of hepatocellular carcinoma.

Authors:  Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

2.  Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype.

Authors:  I Nakano; Y Fukuda; Y Katano; H Toyoda; K Hayashi; T Hayakawa; T Kumada; S Nakano
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

3.  Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Joonho Yoon; Jong In Lee; Soon Koo Baik; Kwang Ho Lee; Joon Hyung Sohn; Hyean Woo Lee; Jun Namkung; Sei Jin Chang; Jong Whan Choi; Hyun Won Kim; Byung-Il Yeh
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

4.  Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences.

Authors:  M Pascu; P Martus; M Höhne; B Wiedenmann; U Hopf; E Schreier; T Berg
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

5.  Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients.

Authors:  K Nagayama; N Enomoto; N Izumi; M Kurosaki; Y Miyasaka; H Watanabe; J Itakura; C H Chen; J Tazawa; Y Hoshino; T Ikeda; F Marumo; C Sato
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

6.  Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a.

Authors:  M I Lusida; M Nagano-Fujii; C A Nidom; R Handajani; T Fujita; K Oka; H Hotta
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

7.  Analysis of mutations within the 5' untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in hepatitis C virus-infected patients in India.

Authors:  Romi Gupta; Murugan Subramani; Mohammed N Khaja; Chandra Madhavi; Swagata Roy; Chittoor M Habibullah; Saumitra Das
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

8.  A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data.

Authors:  Alicia Amadoz; Fernando González-Candelas
Journal:  Evol Bioinform Online       Date:  2015-02-23       Impact factor: 1.625

9.  Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response.

Authors:  Cíntia Bittar; Ana Carolina G Jardim; Lilian H T Yamasaki; Artur T L de Queiróz; Claudia M A Carareto; João Renato R Pinho; Isabel Maria V G de Carvalho-Mello; Paula Rahal
Journal:  BMC Infect Dis       Date:  2010-02-23       Impact factor: 3.090

10.  Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.

Authors:  Pascal Veillon; Christopher Payan; Hélène Le Guillou-Guillemette; Catherine Gaudy; Françoise Lunel
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.